BEAM — Beam Therapeutics Cashflow Statement
0.000.00%
Last trade - 00:00- $1.96bn
- $1.11bn
- $63.52m
Annual cashflow statement for Beam Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -195 | -371 | -289 | -133 | -377 |
| Depreciation | |||||
| Non-Cash Items | 88.8 | 186 | 45.8 | 79.8 | 118 |
| Unusual Items | |||||
| Purchased R&D | |||||
| Equity in Net Earnings/Losses | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 5.35 | 111 | 252 | -116 | -110 |
| Change in Accounts Receivable | |||||
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | -95.7 | -66.3 | 22.5 | -149 | -347 |
| Capital Expenditures | -16.4 | -46.8 | -49 | -33.7 | -8.95 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | -83.8 | -247 | -412 | 106 | 194 |
| Sale of Business | |||||
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Cash from Investing Activities | -100 | -294 | -461 | 71.8 | 185 |
| Financing Cash Flow Items | -2.06 | -8.82 | -0.188 | -0.631 | 0 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 322 | 756 | 112 | 276 | 7.74 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 126 | 396 | -327 | 199 | -155 |